511 related articles for article (PubMed ID: 9506724)
21. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma.
Hofstra RM; Fattoruso O; Quadro L; Wu Y; Libroia A; Verga U; Colantuoni V; Buys CH
J Clin Endocrinol Metab; 1997 Dec; 82(12):4176-8. PubMed ID: 9398735
[TBL] [Abstract][Full Text] [Related]
22. "Cold" single-strand conformational variants for mutation analysis of the RET protooncogene.
Musholt PB; Musholt TJ; Goodfellow PJ; Zehnbauer BA; Wells SA; Moley JF
Surgery; 1997 Aug; 122(2):363-70; discussion 370-1. PubMed ID: 9288142
[TBL] [Abstract][Full Text] [Related]
23. Mutation of RET codon 768 is associated with the FMTC phenotype.
Boccia LM; Green JS; Joyce C; Eng C; Taylor SA; Mulligan LM
Clin Genet; 1997 Feb; 51(2):81-5. PubMed ID: 9111992
[TBL] [Abstract][Full Text] [Related]
24. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA
Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675
[TBL] [Abstract][Full Text] [Related]
25. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
[TBL] [Abstract][Full Text] [Related]
26. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations.
Fitze G; Schierz M; Bredow J; Saeger HD; Roesner D; Schackert HK
Ann Surg; 2002 Nov; 236(5):570-5. PubMed ID: 12409662
[TBL] [Abstract][Full Text] [Related]
27. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
[TBL] [Abstract][Full Text] [Related]
28. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
Uchino S; Noguchi S; Yamashita H; Sato M; Adachi M; Yamashita H; Watanabe S; Ohshima A; Mitsuyama S; Iwashita T; Takahashi M
Jpn J Cancer Res; 1999 Nov; 90(11):1231-7. PubMed ID: 10622534
[TBL] [Abstract][Full Text] [Related]
29. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
[TBL] [Abstract][Full Text] [Related]
30. [Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)].
Komminoth P; Muletta-Feurer S; Soltermann A; Gemsenjäger E; Bürgi H; Staub JJ; Schönle E; Fried M; Vetter W; Spinas GA; Heitz PU
Schweiz Med Wochenschr; 1996 Aug; 126(31-32):1329-38. PubMed ID: 8765374
[TBL] [Abstract][Full Text] [Related]
31. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
Eng C; Clayton D; Schuffenecker I; Lenoir G; Cote G; Gagel RF; van Amstel HK; Lips CJ; Nishisho I; Takai SI; Marsh DJ; Robinson BG; Frank-Raue K; Raue F; Xue F; Noll WW; Romei C; Pacini F; Fink M; Niederle B; Zedenius J; Nordenskjöld M; Komminoth P; Hendy GN; Mulligan LM
JAMA; 1996 Nov; 276(19):1575-9. PubMed ID: 8918855
[TBL] [Abstract][Full Text] [Related]
32. RET protooncogene mutations in patients with apparently sporadic medullary thyroid carcinoma.
Huang CN; Wu SL; Chang TC; Huang SH; Chang TJ
J Formos Med Assoc; 1998 Aug; 97(8):541-6. PubMed ID: 9747064
[TBL] [Abstract][Full Text] [Related]
33. [Molecular diagnosis of multiple type 2 endocrine neoplasia].
Amosenko FA; Pushkash K; Frilling A; Kozlova VN; Liubchenko LN; Kazubskaia TP; Brelysh KE; Gar'kavtseva RF; Kalinin VN
Vestn Ross Akad Med Nauk; 2001; (2):34-7. PubMed ID: 11338505
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
Kambouris M; Jackson CE; Feldman GL
Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
[TBL] [Abstract][Full Text] [Related]
35. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
[TBL] [Abstract][Full Text] [Related]
36. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma.
Wohllk N; Cote GJ; Bugalho MM; Ordonez N; Evans DB; Goepfert H; Khorana S; Schultz P; Richards CS; Gagel RF
J Clin Endocrinol Metab; 1996 Oct; 81(10):3740-5. PubMed ID: 8855832
[TBL] [Abstract][Full Text] [Related]
37. A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma.
Alemi M; Lucas SD; Sällström JF; Bergholm U; Akerström G; Wilander E
Oncogene; 1997 May; 14(17):2041-5. PubMed ID: 9160884
[TBL] [Abstract][Full Text] [Related]
38. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain.
Sánchez B; Robledo M; Biarnes J; Sáez ME; Volpini V; Benítez J; Navarro E; Ruiz A; Antiñolo G; Borrego S
J Med Genet; 1999 Jan; 36(1):68-70. PubMed ID: 9950371
[TBL] [Abstract][Full Text] [Related]
39. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
[TBL] [Abstract][Full Text] [Related]
40. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain.
Bugalho MJ; Frade JP; Santos JR; Limbert E; Sobrinho L
Eur J Endocrinol; 1997 Apr; 136(4):423-6. PubMed ID: 9150704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
